» Articles » PMID: 22956938

Barrier-restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives

Overview
Publisher Wiley
Specialty Dermatology
Date 2012 Sep 8
PMID 22956938
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an "itch-scratch" cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier. Emollients, both creams and ointments, improve the barrier function of stratum corneum by providing it with water and lipids. Studies on atopic dermatitis and barrier repair treatment show that adequate lipid replacement therapy reduces the inflammation and restores epidermal function. Efforts directed to develop immunomodulators that interfere with cytokine-induced skin barrier dysfunction, provide a promising strategy for treatment of atopic dermatitis. Moreover, an impressive proliferation of more than 80 clinical studies focusing on topical treatments in atopic dermatitis led to growing expectations for better therapies.

Citing Articles

The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.

Erdem Y, Ntousounous O, Ozkaya E Sisli Etfal Hastan Tıp Bul. 2025; 58(4):477-482.

PMID: 39816422 PMC: 11729828. DOI: 10.14744/SEMB.2024.46144.


Acne Vulgaris, Atopic Dermatitis and Rosacea: The Role of the Skin Microbiota-A Review.

Condro G, Guerini M, Castello M, Perugini P Biomedicines. 2022; 10(10).

PMID: 36289784 PMC: 9599554. DOI: 10.3390/biomedicines10102523.


Recent insights into the management of treatment-resistant pediatric atopic dermatitis.

Naik P Int J Womens Dermatol. 2022; 8(2):e023.

PMID: 35647254 PMC: 9132517. DOI: 10.1097/JW9.0000000000000023.


A double-blinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in treatment of canine atopic dermatitis.

Kaur G, Ramirez A, Xie C, Clark D, Dong C, Maki C Vet Res Commun. 2021; 46(1):251-260.

PMID: 34713306 DOI: 10.1007/s11259-021-09853-9.


JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results.

Szalus K, Trzeciak M, Nowicki R Microorganisms. 2020; 8(11).

PMID: 33172122 PMC: 7694787. DOI: 10.3390/microorganisms8111743.


References
1.
Proksch E, Folster-Holst R, Jensen J . Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci. 2006; 43(3):159-69. DOI: 10.1016/j.jdermsci.2006.06.003. View

2.
Krakowski A, Dohil M . Topical therapy in pediatric atopic dermatitis. Semin Cutan Med Surg. 2008; 27(2):161-7. DOI: 10.1016/j.sder.2008.04.003. View

3.
Darmstadt G, Saha S, Nawshad Uddin Ahmed A, Choi Y, Chowdhury M, Islam M . Effect of topical emollient treatment of preterm neonates in Bangladesh on invasion of pathogens into the bloodstream. Pediatr Res. 2007; 61(5 Pt 1):588-93. DOI: 10.1203/pdr.0b013e3180459f75. View

4.
Macharia W, Anabwani G, Owili D . Effects of skin contactants on evolution of atopic dermatitis in children: a case control study. Trop Doct. 1991; 21(3):104-6. DOI: 10.1177/004947559102100305. View

5.
Macheleidt O, Kaiser H, Sandhoff K . Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002; 119(1):166-73. DOI: 10.1046/j.1523-1747.2002.01833.x. View